



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Benner et al.

Serial No.: 10/821,256

Filed: April 8, 2004

For: COMPOSITIONS CAPABLE OF  
REDUCING ELEVATED BLOOD UREA  
CONCENTRATION

Confirmation No.: 1851

Examiner: Y. Kim

Group Art Unit: 1644

Attorney Docket No.: 2183.03-6420US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 31, 2007  
Date

Betty Vowles  
Signature

Betty Vowles  
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

01/03/2008 ATRINH 00000021 10821256  
01 FC:1806 180.00 OP

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 2002/0147306 A1	10-2002	Lin et al.
US - 2003/0148955	08-2003	Pluenneke
US - 2004/0208885 A1	10-21-2004	Khan et al.
US - 2005/0037430 A1	02-17-2005	Khan et al.
US - 2005/0107314 A1	05-2005	Gorczynski et al.
US - 2005/0214943 A1	09-29-2005	Khan et al.
US - 2005/0227925 A1	10-13-2005	Benner et al.
US - 2006/0111292 A1	05-25-2006	Khan et al.
US - 2006/0142205 A1	06-29-2006	Benner et al.
US - 4,330,466	05-1982	Yanaihara et al.
US - 4,427,660	01-1984	Schiffman et al.
US - 4,571,336	02-1986	Houck et al.
US - 4,753,965	06-1988	Stemerick et al.
US - 4,855,285	08-1989	Stevens
US - 5,002,961	03-1991	Dage et al.
US - 5,055,447	10-1991	Palladino et al.
US - 5,223,397	06-1993	Pouletty
US - 5,801,193	09-1998	Ojo-Amaize et al.
US - 5,854,004	12-1998	Czemilofsky et al.
US - 5,856,440	01-1999	Wang
US - 5,942,494	08-1999	Ginsberg et al.
US - 5,972,924	10-1999	Keep et al.
US - 5,966,712	10-12-1999	Sabatini et al.
US - 5,981,486	11-1999	Matsushima et al.
US - 5,994,126	11-1999	Steinman et al.

**Serial No.: 10/821,256**

US - 6,051,596	04-2000	Badger
US - 6,075,150	06-2000	Wang et al.
US - 6,150,500	11-2000	Salerno
US - 6,235,281	05-2001	Stenzel et al.
US - 6,278,794	08-21-2001	Parekh et al.
US - 6,310,041	10-2001	Haddox et al.
US - 6,361,992	03-2002	Szkudlinski et al.
US - 6,379,970	04-30-2002	Liebler et al.
US - 6,416,959	07-2002	Giuliano et al.
US - 6,507,788	01-14-2003	Camara y Ferrer et al.
US - 6,539,102	03-25-2003	Anderson et al.
US - 6,630,138	10-2003	Gerlitz et al.
US - 6,711,563	03-23-2004	Koskas
US - 6,831,057	12-2004	Baldwin et al.
US - 6,844,315	1-2005	Khan et al.
US - 6,921,751	07-26-2005	Khan et al.
US - 7,175,679	02-2007	Khan et al.

#### Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 98/34631 A1	08-1998	Thomas Jefferson University
WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.

#### Other Documents

ABEYAMA et al., A role of NF- $\kappa$ B-dependent gene transactivation in sunburn. The Journal of Clinical Investigation, Vol. 105, No. 12, pp. 1751-59, June 2000.

ABRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.

ADIB-CONQUY et al., "NF- $\kappa$ B Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," *Am. J. Respir. Crit. Care Med.*, 2000, pp. 1877-1883, Vol. 162.

ARIMA et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," *Leukemia Research*, 1998, pp. 265-273, Vol. 22, No. 3.

BAEUEERLE et al., "Function and Activation of NF- $\kappa$ B in the Immune System," *Annu. Rev. Immunol.*, 1994, pp. 141-179, Vol. 12.

BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor- $\kappa$ B Activation," *The Journal of Neuroscience*, 1 May 1998, pp. 3251-3260, Vol. 18, No. 9.

BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" *Mental Retardation and Developmental Disabilities Research Reviews*, 2004, pp. 318-326, Vol. 10.

BRADHAM et al., Activation of nuclear factor-  $\kappa$ B during orthotopic liver transplantation in rats is protective and does not require Kupffer cells, *Liver Transplantation and Surgery*, July 1999, pp. 282-93, Vol. 5, No. 4.

BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," *Journal of Interferon and Cytokine Research*, 1997, pp. 295-306, Vol. 17.

COOK et al., Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis, *Journal of Neurological Sciences*, Vol. 152, pp. 172-81, 1997.

CUI et al., *Am. J. Physiol. Integr. Comp. Physiol.*, 2004, pp. R699-R709, Vol. 286.

DE SAIZIEU et al., *Journal of Bacteriology*, Vol. 182, No. 17, pp. 4696-4703, September 2000.

DECHEND et al., *Oncogene*, Vol. 18, pp. 3316-3323, 1999.

EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," *Science*, 22 December 1989, pp. 1617-1620, Vol. 246.

EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," *Oncogene*, 1999, pp. 6896-6909, Vol. 18.

FASSIO et al., Transforming Growth Factor Alpha and Its Receptor in Neural Retina, Investigative Ophthalmology & Visual Science, September 1989, pp. 1916-1922, Vol. 30, No. 9.

FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliere's Clinical Haematology, 2000, 179-197, Vol. 13. No. 2.

FLORES et al., NFkappaB and AP-1 DNA binding activity in patients with multiple sclerosis. J. Neuroimmunol. Vol. 135, No. 1-2, pp. 141-7, February 2003.

GenBank Accession No. NP\_000728, GI: 4502789, publicly available April 2007.

HAN et al., Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation, American Journal of Physiology, July 1999, Vol. 277, pp. C74-C82.

ICHIYAMA et al., Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation, Brain Research, July 1999, pp. 31-37, Vol. 836.

JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," Ann. N.Y Acad. Sci., 2005, pp. 148-150, Vol. 1053.

KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, Vol. 292.

KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.

Keeton and Gould, Biological Science, 5th Ed., New York, W.W. Norton & Company, Inc. 1993, p. 4.

KIDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review, 2002, pp. 472-499, Vol. 7, No. 6.

KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.

LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.

LIN et al., The Journal of Biological Chemistry, Vol. 270, No. 24, pp. 14255-58, June 1995.

MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.

MALYAK et al., Characterization of a Low Molecular Weight Isoform of IL-1 Receptor Antagonist, The Journal of Immunology, 1998, pp. 1997-2003, Vol. 161.

MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.

MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.

MOAYERI et al., Journal of Clinical Investigation, September 2003, pp. 670-82, Vol. 112, No. 5.

NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.

OHLSSON et al., Interleukin-1 Receptor Antagonist Reduces Mortality from Endotoxin Shock, Nature, Dec. 6, 1990, pp. 550-552, Vol. 348.

OKA et al., Immunosuppression in organ transplantation, Japanese Journal of Pharmacology, Vol. 71, No 2, pp. 89-100, June 1996.

OLSZYNA et al., Levels of Inhibitors of Tumor Necrosis Factor Alpha and Interleukin 1b in Urine and Sera of Patients with Urosepsis, Infection and Immunity, Aug. 1998, pp. 3527-34.

PCT International Search Report, International Application No. PCT/NL02/00639, mailed August 4, 2003.

PCT International Search Report, PCT/NL01/00259, dated December 18, 2001.

PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462.

SAMANIEGO et al., "Induction of Programmed Cell Death in Kaposi's Sarcoma Cells by Preparations of Human Chorionic Gonadotropin," Journal of the National Cancer Institute, January 20, 1999, pp. 135-43, Vol. 91, No. 2.

SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.

TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.

WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neutrophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.

YANG et al., "Increased cortical nuclear factor  $\kappa$ B (NF- $\kappa$ B) DNA binding activity after traumatic brain injury in rats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.

ZHOU et al., Transplantation tolerance in NF- $\kappa$ B-impaired mice is not due to regulation but is prevented by transgenic expression of Bcl-xL. The Journal of Immunology, Vol. 174, No. 6, pp. 3447-53, March 2005.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2183.03-5957.1US  
Serial No.: 11/593,329  
Filing Date: 11/6/2006  
Title: TREATMENT OF ISCHEMIC EVENTS

Attorney Docket No.: 2183.03-7996US  
Serial No.: 11/600,294  
Filing Date: 11/15/2006  
Title: OLIGOPEPTIDE ACETATE AND FORMULATIONS THEREOF

Attorney Docket No.: 2183-8204US  
Serial No.: 11/706,176  
Filing Date: 2/12/2007  
Title: OLIGOPEPTIDE TREATMENT OF ISCHEMIA-REPERFUSION INJURY

Attorney Docket No.: 2183 8237US  
Serial No.: 11/715,314  
Filing Date: 3/7/2007  
Title: CONTROL OF RADIATION INJURY

**Serial No.: 10/821,256**

Attorney Docket No.: 2183.03 6084.1US  
Serial No.: 11/859,265  
Filing Date: 9/21/2007  
Title: IMMUNOREGULATORY COMPOSITIONS

Attorney Docket No.: 2183.03-7350.2US  
Serial No.: 11/975,284  
Filing Date: 10/17/2007  
Title: TREATMENT FOR TUMORS

Attorney Docket No.: 2183.03-8626US  
Serial No.: 11/981,491  
Filing Date: 10/30/2007  
Title: TREATMENT OF IATROGENIC DISEASE

Attorney Docket No.: 2183.03-8625US  
Serial No.: 11/981,505  
Filing Date: 10/30/2007  
Title: TREATMENT OF BURNS

Attorney Docket No.: 2183.03-5959.1US  
Serial No.: 11/982,170  
Filing Date: 10/31/2007  
Title: ADMINISTRATION OF GENE-REGULATORY PEPTIDES

Attorney Docket No.: 2183.03-8628US  
Serial No.: 11/982,292  
Filing Date: 10/31/2007  
Title: TREATMENT OF NEUROLOGICAL DISORDERS

Attorney Docket No.: 2183.03-8629US  
Serial No.: 11/982,293  
Filing Date: 10/31/2007  
Title: STRATIFICATION

Attorney Docket No.: 2183-8205US  
Serial No.: 60/901,155  
Filing Date: 2/12/2007  
Title: TREATMENT OF TRAUMA-HEMORRHAGE WITH SHORT OLIGOPEPTIDES



Serial No.: 10/821,256

Attorney Docket No.: 2183-8238US  
Serial No.: 60/905,468  
Filing Date: 3/7/2007  
Title: CONTROL OF NUCLEIC ACID SYNTHESIS


Attorney Docket No.: 2183.03-8278US  
Serial No.: 60/922,712  
Filing Date: 4/10/2007  
Title: METHODS FOR IDENTIFYING BIOLOGICALLY ACTIVE  
PEPTIDES AND PREDICTING THEIR FUNCTION

Attorney Docket No.: 2183.03-8205.1US  
Serial No.: 60/961,841  
Filing Date: 7/23/2007  
Title: TREATMENT OF TRAUMA-HEMORRHAGE WITH SHORT  
OLIGOPEPTIDES

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Allen C. Turner  
Registration No. 33,041  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: December 31, 2007  
ACT/bv

Enclosures: Form PTO/SB/08  
Cited Non-U.S. Patent Documents  
Check in the amount of \$180.00

Document in ProLaw